ROCKWELL MEDICAL, INC. Form DEFC14A: Definitive proxy statement in a contested solicitation
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-04-21: Form DEFC14A; Description DEFC14A; Document a2231890zdefc14a.htm.
- 2017-04-20: Form DEFC14A; Description Definitive proxy statement in a contested solicitation; Document defc14a11265002_04202017.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2017-04-21 | DEFC14A | DEFC14A | a2231890zdefc14a.htm | |
| 2017-04-20 | DEFC14A | Definitive proxy statement in a contested solicitation | defc14a11265002_04202017.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |